Although novel therapeutic approaches, including CAR-T and anti-PD-1 therapy, have been developed to address malignant tumor progression, the treatment paradigm still follows the traditional model of single-target and single-drug therapy, often failing to fully consider the cancer immunoediting process. Here, PDCD1 is linked to cancer.